FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Supreme Court Rejects Mifepristone Lawsuit

The U.S. Supreme Court 6/13 unanimously rejects a lawsuit seeking to sharply restrict distribution of the chemical abortion pill mifepristone (Dancos ...

Biologics

FDA Revises Covid Vaccine Composition Recommendation

FDA updates its advice on this falls Covid-19 vaccine composition based on a recent review of circulating Covid cases in the U.S.

Biologics

Submit Long Covid Drug as IND: FDA

FDA says Revive Therapeutics should submit an IND for a clinical trial of its bucillamine as a treatment for Long Covid.

latest-news-card-1
Federal Register

Drug Distribution Security Comment Period Reopened

Federal Register notice: FDA reopens the comment period on an 11/20/2023 request for information that is intended to better understand the status of t...

latest-news-card-1
Federal Register

Info Collection on Drug Compounding

Federal Register notice: FDA seeks comments on an information collection extension entitled Human Drug Compounding, Repackaging, and Related Activitie...

latest-news-card-1
Human Drugs

5 Teva ProAir Patents Ordered Out of Orange Book

A New Jersey federal judge orders five Teva ProAir patents removed from the FDA Orange Book.

latest-news-card-1
Human Drugs

FDA Platform Technology Designation Analyzed

Two Morgan Lewis attorneys analyze a recent FDA guidance on how it will implement its drug platform technology designation program.

latest-news-card-1
Human Drugs

Positive Results for Setrusumab in Bone Disease

Ultragenyx and BioMereo say their setrusumab showed positive results in the Phase 2 portion of the Orbit study in patients with the complex bone and t...

latest-news-card-1
Human Drugs

FDA OKs Lillys Retevmo for Some Thyroid Cancers

FDA gives traditional approval to Lillys Retevmo for some thyroid cancers in patients aged two and up.

latest-news-card-1
FDA General

Appropriators Slash FDA Budget by $450 Million

A House Appropriations subcommittee slashes $450 million (6%) from FDAs fiscal year 2025 budget.